Viewing Study NCT04787211



Ignite Creation Date: 2024-05-06 @ 3:52 PM
Last Modification Date: 2024-10-26 @ 1:58 PM
Study NCT ID: NCT04787211
Status: COMPLETED
Last Update Posted: 2023-03-03
First Post: 2021-03-04

Brief Title: A Study of Human Monoclonal Antibodies BRII-196 and BRII-198
Sponsor: Brii Biosciences Limited
Organization: Brii Biosciences Limited

Study Overview

Official Title: A Phase 2 Study to Evaluate the Safety and Efficacy of Human Monoclonal Antibodies BRII-196 and BRII-198 Administered by Intravenous Infusion for the Treatment of COVID-19 Patients
Status: COMPLETED
Status Verified Date: 2023-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The aim of this phase 2 study is to evaluate the safety and efficacy of single dose IV infusion of BRII-196 and BRII-198 given as combination therapy in patients with severe COVID-19 and mild to moderate COVID-19 and asymptomatic carrier
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: None